Meeting
2019 Genitourinary Cancers Symposium
Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
Authors
Dylan J Martini
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
Dylan J Martini , Julie M. Shabto , Yuan Liu , Bradley Curtis Carthon , Alexandra Speak , Elise Hitron , Greta Russler , Sarah Caulfield , Kenneth Ogan , Wayne Harris , Viraj A. Master , Omer Kucuk , Mehmet Asim Bilen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 671)
DOI
10.1200/JCO.2019.37.7_suppl.671
Abstract #
671
Poster Bd #
K2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.
First Author: Thomas Hilser
Poster
2021 ASCO Annual Meeting
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
First Author: Elizabeth R Kessler
Poster
2019 Genitourinary Cancers Symposium
Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
First Author: Dylan J Martini
Poster
2022 ASCO Genitourinary Cancers Symposium
Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
First Author: Jeffrey Graham